Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 30 September 2022, including: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after lecanemab results; Leqvio’s importance to Novartis AG; Pfizer Inc.’s secret sauce for digitization; and Amgen, Inc.’s clinical trial diversity initiatives.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "A Banner Moment For Alzheimer's Positions Eisai/Biogen At The Head Of The Pack" - Scrip, 27 Sep, 2022.)
(Also see "Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen’s Lecanemab Readout" - Scrip, 28 Sep, 2022.)
(Also see "Leqvio Launch Will Be Fundamental To Success Of New Novartis" - Scrip, 23 Sep, 2022.)
(Also see "Pfizer Reveals Secret Digital Sauce To Cut Trial Duration, MLR Review Times" - Scrip, 28 Sep, 2022.)
(Also see "Amgen VP Encouraged By Initial Clinical Trial Diversity Efforts" - Scrip, 26 Sep, 2022.)